Stock HOOK HOOKIPA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
0.98 USD +14.34% Intraday chart for HOOKIPA Pharma Inc. +14.09% +20.99%
May. 09 HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Transcript : HOOKIPA Pharma Inc. - Special Call

Business Summary

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Number of employees: 165

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
14 100.0 % 20 100.0 % +41.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
14 100.0 % 20 100.0 % +41.27%

Managers

Managers TitleAgeSince
Jörn Aldag CEO
 Chief Executive Officer 65 16-05-31
Reinhard Kandera DFI
 Director of Finance/CFO 54 17-03-31
Klaus Orlinger CTO
 Chief Tech/Sci/R&D Officer 46 12-01-31
Roman Necina COO
 Chief Operating Officer 56 19-10-31
Tony Melckenbeek PRN
 Corporate Officer/Principal - -
Victor Paulus LAW
 General Counsel - 18-08-31

Members of the board

Members of the board TitleAgeSince
Jörn Aldag CEO
 Chief Executive Officer 65 16-05-31
Jan van de Winkel CHM
 Chairman 63 17-09-30
Reinhard Kandera DFI
 Director of Finance/CFO 54 17-03-31
Julie O'Neill BRD
 Director/Board Member 58 18-10-31
Malte Peters BRD
 Director/Board Member 61 22-12-31
Mary Coelho BRD
 Director/Board Member 62 23-04-02
David Kaufman BRD
 Director/Board Member 51 19-04-24
Timothy Reilly BRD
 Director/Board Member 50 22-04-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 2,399,517 0 0 78.47 %
Stock B 1 96,550,590 77,641,224 ( 80.42 %) 0

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
19.43 %
18,759,465 19.43 % 15 M $
Baker Bros. Advisors LP
8.419 %
8,128,151 8.419 % 7 M $
Artal Group SA
5.869 %
5,666,410 5.869 % 5 M $
Knoll Capital Management LP
5.715 %
5,517,385 5.715 % 4 M $
EcoR1 Capital, LLC
4.759 %
4,595,024 4.759 % 4 M $
Fidelity Management & Research Co. LLC
3.478 %
3,358,383 3.478 % 3 M $
Sofinnova Partners SAS
3.255 %
3,142,596 3.255 % 3 M $
Vanguard Global Advisers LLC
2.194 %
2,118,416 2.194 % 2 M $
Morgan Stanley Capital Services LLC
1.284 %
1,240,072 1.284 % 999 498 $
Redmile Group LLC
1.102 %
1,063,769 1.102 % 857 398 $
NameEquities%Valuation
Redmile Group LLC
78.78 %
2,346 78.78 % 1 891 $
NameEquities%Valuation
EcoR1 Capital, LLC
31.47 %
4,973 31.47 % 4 008 $

Company contact information

HOOKIPA Pharma, Inc.

350 Fifth Avenue 72nd floor, Suite 7240

10118, New York

+

http://www.hookipapharma.com
address HOOKIPA Pharma Inc.(HOOK)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for HOOKIPA Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.98 USD
Average target price
4.6 USD
Spread / Average Target
+369.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HOOKIPA PHARMA INC. Stock HOOKIPA Pharma Inc.
+20.99% 96.97M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.74% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.65% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.07% 369B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.25% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.99% 282B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.43% 244B
NOVARTIS AG Stock Novartis AG
+9.79% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-4.54% 205B
AMGEN INC. Stock Amgen Inc.
+7.43% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HOOK Stock
  4. Company HOOKIPA Pharma Inc.
equities